Clinical Management of Congenital Hypogonadotropic Hypogonadism.

Fiche du document

Auteurs
Date

1 avril 2019

Types de document
Périmètre
Langue
Identifiants
Source

Serveur académique Lausannois

Relations

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1210/er.2018-00116

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/30698671

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1945-7189

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_87D1B3A2F09F3

Collection

Serveur Académique Lausannois

Organisation

Université de Lausanne et CHUV

Licences

info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer

Mots-clés 0

Adolescent; Adult; Female; Gonadotropin-Releasing Hormone/administration & dosage; Gonadotropin-Releasing Hormone/deficiency; Gonadotropin-Releasing Hormone/metabolism; Gonadotropins/administration & dosage; Humans; Hypogonadism/congenital; Hypogonadism/diagnosis; Hypogonadism/drug therapy; Hypogonadism/metabolism; Infant; Infant, Newborn; Male

Sujets proches En

Therapy

Citer ce document

J. Young et al., « Clinical Management of Congenital Hypogonadotropic Hypogonadism. », Serveur académique Lausannois, ID : 10.1210/er.2018-00116

Métriques

Partage / Export

Résumé 0

The initiation and maintenance of reproductive capacity in humans is dependent on pulsatile secretion of the hypothalamic hormone GnRH. Congenital hypogonadotropic hypogonadism (CHH) is a rare disorder that results from the failure of the normal episodic GnRH secretion, leading to delayed puberty and infertility. CHH can be associated with an absent sense of smell, also termed Kallmann syndrome, or with other anomalies. CHH is characterized by rich genetic heterogeneity, with mutations in >30 genes identified to date acting either alone or in combination. CHH can be challenging to diagnose, particularly in early adolescence where the clinical picture mirrors that of constitutional delay of growth and puberty. Timely diagnosis and treatment will induce puberty, leading to improved sexual, bone, metabolic, and psychological health. In most cases, patients require lifelong treatment, yet a notable portion of male patients (∼10% to 20%) exhibit a spontaneous recovery of their reproductive function. Finally, fertility can be induced with pulsatile GnRH treatment or gonadotropin regimens in most patients. In summary, this review is a comprehensive synthesis of the current literature available regarding the diagnosis, patient management, and genetic foundations of CHH relative to normal reproductive development.

document thumbnail

Par les mêmes auteurs

Sur les mêmes sujets

Exporter en